NATCOPHARM News Today

Natco Pharma Ltd Share Price

NATCOPHARM

CMP as on 04-Mar-24 9:24
₹ 1,004

icon 10.35 | 1.04%

Open
₹ 1,000
Turnover(lac)
₹ 299
Prev. Close
₹ 993.65
Day's Vol (shares)
₹ 29,780
Day's Vol (shares)
₹ 998.00         ₹ 1,008.95

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
Blog Image

Kutch Copper Ltd (KCL), a subsidiary of Adani Enterprises Ltd, intends to begin operations in the coming weeks.

  • 01 March, 2024
  • 12:20 PM
  • less than a minute
Image not found

Under the terms of the agreement, the product may be introduced in the US in February 2025 after receiving FDA approval.

  • 01 March, 2024
  • 11:31 AM
  • less than a minute
Image not found

According to a press release from Suven Pharmaceuticals, the entire deal is anticipated to be completed within the next 12 to 15 months

  • 01 March, 2024
  • 11:12 AM
  • less than a minute
Image not found

Aurobindo Pharma markets its products in over 125 countries, with key partners like AstraZeneca and Pfizer

  • 01 March, 2024
  • 10:27 AM
  • less than a minute
Image not found

Promoters Srinivasan K Swamy and Narasimhan Krishnaswamy will be selling a significant portion of equity shares through OFS

  • 01 March, 2024
  • 10:09 AM
  • less than a minute
Blog Image

The US private equity group is trying to employ financial consultants.

  • 29 February, 2024
  • 11:40 AM
  • less than a minute
Image not found

Top gainers on the Nifty included Tata Motors, TCS, IndusInd Bank, Power Grid Corp, and Sun Pharma.

  • 27 February, 2024
  • 3:39 PM
  • less than a minute
Image not found

A press release issued by One97 Communications Ltd highlighted the appointment of several new members to the PPBL Board

  • 27 February, 2024
  • 9:00 AM
  • less than a minute
Image not found

The Mohali facility has been under USFDA scrutiny, and corrective actions were directed by the regulator.

  • 26 February, 2024
  • 12:43 PM
  • less than a minute
Image not found

A Form-483 with two observations was issued following the examination.

  • 26 February, 2024
  • 11:37 AM
  • less than a minute